Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Late Phase 2 Study of Paricalcitol Injection: Dose-response Study of Paricalcitol Injection in Chronic Kidney Disease Subjects Receiving Hemodialysis With Secondary Hyperparathyroidism (Examination of Initial Dose and Incremental Dose)

NCT00667576 is registered in ClinicalTrials.gov with Abbott as lead sponsor.

NCT NCT00667576
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00667576 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Late Phase 2 Study of Paricalcitol Injection: Dose-response Study of Paricalcitol Injection in Chronic Kidney Disease Subjects Receiving Hemodialysis With Secondary Hyperparathyroidism (Examination of Initial Dose and Incremental Dose)
Lead sponsor
Abbott
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2008
Completion date
March 31, 2009
Enrollment
153 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

chronic kidney disease on hemodialysis, secondary hyperparathyroidism